Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial)

被引：4

作者：

Foa, Robin ^{[1
]}

Schuh, Anna ^{[2
]}

Zaritskey, Andrey ^{[3
]}

Semochkin, Sergey ^{[4
]}

Simpson, David ^{[5
]}

Egyed, Miklos ^{[6
]}

Vokurka, Samuel ^{[7
]}

Kassis, Jeannine ^{[8
]}

Zhang, Jennie ^{[9
]}

Purse, Brendan ^{[9
]}

Chanan-Khan, Asher A. ^{[10
]}

机构：

[1] Univ Sapienza, Policlin Umberto 1, Rome, Italy

[2] Univ Oxford, Oxford, England

[3] St Petersburg State Med Univ, St Petersburg, Russia

[4] Pirogov Russian Natl Res Med Univ, Moscow, Russia

[5] North Shore Hosp, Auckland, New Zealand

[6] Kaposi Mor Teaching Hosp, Dept Internal Med, Kaposvar, Hungary

[7] Univ Hosp Plzen, Plzen, Czech Republic

[8] Hop Maison Neuve Rosemont, Montreal, PQ, Canada

[9] Celgene Corp, Summit, NJ USA

[10] Mayo Clin, Div Hematol, Jacksonville, FL USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.230.230

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

230

引用

页数：5

共 50 条

[21] Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase
陈怡琳
ChinaMedicalAbstracts(InternalMedicine), 2019, 36 (03) : 181 - 181
[22] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
Chanan-Khan, Asher
Miller, Kena C.
Musial, Laurie
Lawrence, David
Padmanabhan, Swaminathan
Takeshita, Kenichi
Porter, Carl W.
Goodrich, David W.
Bernstein, Zale P.
Wallace, Paul
Spaner, David
Mohr, Alice
Byrne, Catriona
Hernandez-Ilizaliturri, Francisco
Chrystal, Cynthia
Starostik, Petr
Czuczman, Myron S.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5343 - 5349
[23] Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
Wendtner, Clemens-Martin
Hillmen, Peter
Mahadevan, Daruka
Buehler, Andreas
Uharek, Lutz
Coutre, Steven
Frankfurt, Olga
Bloor, Adrian
Bosch, Francesc
Furman, Richard R.
Kimby, Eva
Gribben, John G.
Gobbi, Marco
Dreisbach, Luke
Hurd, David D.
Sekeres, Mikkael A.
Ferrajoli, Alessandra
Shah, Sheetal
Zhang, Jennie
Moutouh-de Parseval, Laure
Hallek, Michael
Heerema, Nyla A.
Stilgenbauer, Stephan
Chanan-Khan, Asher A.
LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 417 - 423
[24] Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ammann, Eric M.
Shanafelt, Tait D.
Larson, Melissa C.
Wright, Kara B.
McDowell, Bradley D.
Link, Brian K.
Chrischilles, Elizabeth A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (12): : E11 - E25
[25] BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study
Roeker, Lindsey E.
Han, Yi
Teschemaker, Anna
Mato, Anthony R.
Thompson, Meghan C.
AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (04) : 720 - 723
[26] Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Badoux, Xavier C.
Keating, Michael J.
Wen, Sijin
Wierda, William G.
O'Brien, Susan M.
Faderl, Stefan
Sargent, Rachel
Burger, Jan A.
Ferrajoli, Alessandra
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) : 584 - 591
[27] Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment
Okada, Masaya
Imagawa, Jun
Tanaka, Hideo
Nakamae, Hirohisa
Hino, Masayuki
Murai, Kazunori
Ishida, Yoji
Kumagai, Takashi
Sato, Seiichi
Ohashi, Kazuteru
Sakamaki, Hisashi
Wakita, Hisashi
Uoshima, Nobuhiko
Nakagawa, Yasunori
Minami, Yosuke
Ogasawara, Masahiro
Takeoka, Tomoharu
Akasaka, Hiroshi
Utsumi, Takahiko
Uike, Naokuni
Sato, Tsutomu
Ando, Sachiko
Usuki, Kensuke
Mizuta, Syuichi
Hashino, Satoshi
Nomura, Tetsuhiko
Shikami, Masato
Fukutani, Hisashi
Ohe, Yokiko
Kosugi, Hiroshi
Shibayama, Hirohiko
Maeda, Yasuhiro
Fukushima, Toshihiro
Yamazaki, Hirohito
Tsubaki, Kazuo
Kukita, Toshimasa
Adachi, Yoko
Nataduka, Toshiki
Sakoda, Hiroto
Yokoyama, Hisayuki
Okamoto, Takahiro
Shirasugi, Yukari
Onishi, Yasushi
Nohgawa, Masaharu
Yoshihara, Satoshi
Morita, Satoshi
Sakamoto, Junichi
Kimura, Shinya
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (05): : 353 - +
[28] Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
Mahon, Francois-Xavier
Boquimpani, Carla
Kim, Dong-Wook
Benyamini, Noam
Clementino, Nelma Cristina D.
Shuvaev, Vasily
Ailawadhi, Sikander
Lipton, Jeffrey Howard
Turkina, Anna G.
De Paz, Raquel
Moiraghi, Beatriz
Nicolini, Franck E.
Dengler, Jolanta
Sacha, Tomasz
Takahashi, Naoto
Fellague-Chebra, Rafik
Acharya, Sandip
Wong, Stephane
Jin, Yu
Hughes, Timothy P.
ANNALS OF INTERNAL MEDICINE, 2018, 168 (07) : 461 - +
[29] Phase 3 study of oral lenalidomide as maintenance therapy for patients with B-cell chronic lyouphocylic leukemia (CLL).
Chanan-Khan, Asher Alban Akmal
Zaritskey, Andrey
Egyed, Miklos
Vokurka, Samuel
Samoylova, Olga
Schuh, Anna
Simpson, David
Mei, Jay M.
Oliveira, Natalia
Kong, Oliver
Foa, Robin
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[30] Comparison of Treatment Changes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched From Imatinib to Nilotinib or Dasatinib As Second-Line Therapy
Macalalad, Alexander R.
Chen, Lei
Guerin, Annie
Luo, Jiayuan
Wu, Eric Qiong
Griffin, James D.
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →